Suppr超能文献

2型糖尿病患者高血压的评估与管理

Assessment and management of hypertension in patients with type 2 diabetes.

作者信息

Thomas M C, Atkins R

机构信息

Danielle Alberti Memorial Centre for Diabetes Complications, Baker Medical Research Institute, Melbourne, Victoria, Australia.

出版信息

Intern Med J. 2009 Mar;39(3):143-9. doi: 10.1111/j.1445-5994.2008.01696.x. Epub 2008 Sep 2.

Abstract

BACKGROUND

Hypertension is a major risk factor for adverse outcomes in type 2 diabetes and an important target for intervention. Despite this, the management of blood pressure (BP) remains suboptimal, particularly in patients at increased risk for cardiovascular and chronic kidney disease. The aim of this study was to estimate the frequency of hypertension and its management in consecutive clinic-based samples of patients with type 2 diabetes in Australian primary care.

METHODS

BP levels and antihypertensive management strategies were compared in patients with type 2 diabetes recruited as part of the Developing Education on Microalbuminuria for Awareness of reNal and cardiovascular risk in Diabetes (DEMAND) study in 2003 (n = 1831) and the National Evaluation of the Frequency of Renal impairment cO-existing with Non-insulin-dependent diabetes (NEFRON) study in 2005 (n = 3893). Systolic BP levels and the use of antihypertensive therapies were examined in patients with and without chronic kidney disease.

RESULTS

The patient characteristics in both studies were similar in that more than 80% of patients in both studies were hypertensive. Systolic BP targets of < or =130 mmHg were achieved in approximately half of all treated patients in both studies. However, the use of antihypertensive therapy either alone or in combination increased from 70.4% in DEMAND to 79.5% in NEFRON 2 years later (P < 0.001). Despite this, antihypertensive therapy continued to be underutilized in high-risk groups, including in those with established chronic kidney disease.

CONCLUSION

The DEMAND and NEFRON studies both show that BP control is achievable in Australian general practice, with more than half of all patients seeing their general practitioners achieving a target systolic BP < or =130 mmHg. However, more needs to be done to further reduce BP levels, particularly in patients at high risk of adverse outcomes.

摘要

背景

高血压是2型糖尿病不良结局的主要危险因素,也是重要的干预靶点。尽管如此,血压(BP)管理仍未达到最佳状态,尤其是在心血管疾病和慢性肾脏病风险增加的患者中。本研究的目的是评估澳大利亚初级保健机构中连续的2型糖尿病门诊患者样本中高血压的发生率及其管理情况。

方法

比较了2003年作为糖尿病肾和心血管疾病风险微白蛋白尿发展教育研究(DEMAND)一部分招募的2型糖尿病患者(n = 1831)和2005年非胰岛素依赖型糖尿病合并肾功能损害频率国家评估研究(NEFRON)(n = 3893)的血压水平和降压管理策略。对有和没有慢性肾脏病的患者的收缩压水平和降压治疗的使用情况进行了检查。

结果

两项研究中的患者特征相似,两项研究中均有超过80%的患者患有高血压。两项研究中,所有接受治疗的患者中约有一半达到了收缩压目标≤130 mmHg。然而,单独或联合使用降压治疗的比例从DEMAND研究中的70.4%增加到2年后NEFRON研究中的79.5%(P < 0.001)。尽管如此,包括已确诊慢性肾脏病患者在内的高危人群中降压治疗仍未得到充分利用。

结论

DEMAND和NEFRON研究均表明,在澳大利亚的普通医疗实践中可以实现血压控制,超过一半的看全科医生的患者达到了收缩压目标≤130 mmHg。然而,仍需要进一步努力降低血压水平,尤其是在有不良结局高风险的患者中。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验